AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03999866 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mcgrath mac x-blade
Description: mcgarth mac videolaryngoscope
Study NCT03999866 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: storz c-mac
Description: storz c-mac videolaryngoscope
Study NCT03999866 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: storz d-blade
Description: storz d-blade video laryngoscope
Study NCT00057837 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF will be administered subcutaneously at a dose of 5 mcg/kg once a day starting on day 11 until WBC recovery > 10,000 dL.
Study NCT00057837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Arm PET: 20 mg/m2 IV on days 8, 9 and 10 of each cycle following Etoposide. Arm PIE: 20 mg/m2 IV on days 1 and 8 of each cycle following Irinotecan.
Study NCT01111201 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: The intervention is a self-administered anonymous questionnaire that is voluntarily completed by the patient. Questions in Section One will cover general information about the patient including gender, age, race, country of birth, current zip code of residence, and level of education. Questions in Section Two will cover information regarding the cancer (breast/lymphoma) or transplant (allogeneic/ autologous). Questions in Section Three will cover travel history including the frequency of travel outside the United States and Canada in the last 5 years. Questions in Sections Four through Seven will obtain information about their last trip outside the United States and Canada.
Study NCT01693458 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Appreciative Inquiry Change Agents (CA) program (NAMWEZA)
Description: The intervention is based on an Appreciative Inquiry approach that comprises a 10-session program based on learning by doing rather than factual classroom type learning, although it includes discussion of relevant facts about HIV, and other STIs. The intervention is based on the template of Stepping Stones (Jewkes et al., 2008), which is internationally one of the most widely used participatory behavioral interventions targeting sexual health. The Stepping Stones curriculum was shortened and radically adapted from more than 20 sessions. However NAMWEZA borrows generously from many of the exercises and games. It also employs the successful experience of stratification by age and sex to engage 4 different working groups (younger and older, male and female).
Study NCT01693458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appreciative Inquiry Change Agents (CA) program (NAMWEZA)
Description: The intervention is based on an Appreciative Inquiry approach that comprises a 10-session program based on learning by doing rather than factual classroom type learning, although it includes discussion of relevant facts about HIV, and other STIs. The intervention is based on the template of Stepping Stones (Jewkes et al., 2008), which is internationally one of the most widely used participatory behavioral interventions targeting sexual health. The Stepping Stones curriculum was shortened and radically adapted from more than 20 sessions. However NAMWEZA borrows generously from many of the exercises and games. It also employs the successful experience of stratification by age and sex to engage 4 different working groups (younger and older, male and female).
Study NCT03965832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNT during exercise
Description: 6-minute walking test performed initially on HFNT. HFNT will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) as at baseline conditions during exercise.~Participants will then cross-over to repeat the test on baseline conditions.
Study NCT03965832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard oxygen therapy/RA
Description: 6-minute walking test performed on baseline conditions. Participants will then be cross over to repeat the test on HFNT
Study NCT01255826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resuscitation of preterm neonates by sustained lung inflation through T piece device followed by CPAP
Description: After oropharyngeal and nasal suctioning, if there are no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, the following approach will be followed:Pressure-controlled (20 cm H2O) inflation will be sustained for 15 secs, using a neonatal mask and a T-piece ventilator (NeoPuff Infant Resuscitator; Fisher \& Paykel).To avoid pressure leakage, we will use a neonatal mask of appropriate size which adequately cover both the mouth and nostrils of infants. This pressure controlled inflation will be followed by CPAP at 5 Cm H2O.This procedure will be repeated a second time with a pressure of 25 cm H2O for 15 secs if breathing remained insufficient and/or the heart rate is \< 100 bpm and/or the infant is cyanotic. To be followed by CPAP at 6 Cm H2O.A third puff with a pressure of 30 cm H2O for 15 secs will be used after few seconds if inadequate heart rate and respiration was not reached. This will be followed by CPAP at 7 Cm H2O.
Study NCT03713801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Total daily dose titrated up to 1500 mg po q day over the course of 3 weeks and continued for a total exposure of 12 weeks.
Study NCT03713801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets titrated up to 3 tablets over the course of 3 weeks and then continued as 3 daily for a total exposure of 12 weeks
Study NCT01295047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Study NCT01295047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VERAPAMIL
Description: 240 MG SR
Study NCT01295047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril
Description: 4 MG
Study NCT01015950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plumpy'Sup
Description: Lipid-based (vegetable oil, peanut paste, soy protein-containing) fortified nutrient supplement to provide 500 kcal/d
Study NCT01015950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Local food supplement
Description: Local foods (millet flour, cowpea flour, sugar, vegetable oil) and a multiple micronutrient powder (Mix Me) are provide, according to the national Mali CMAM protocol when special processed foods are not available.
Study NCT01015950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Misola
Description: Locally produced, millet-soy-peanut-based fortified complementary food (Misola)
Study NCT01015950 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SCSB
Description: Processed, fortified, corn-soy-milk-based food blend (SCSB for malnourished children, to be supplied by the World Food Program) to provide an additional 500 kcal/day
Study NCT00309283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-acting somatostatin
Description: Patients randomized to treatment will be given intramuscularly long-acting somatostatin (Sandostatin-LAR, Novartis, Basel) at the dose of 40 mg every 28 days (in two intragluteal 20 mg injections).
Study NCT01255826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resuscitation of preterm neonates by intermittent bag and mask ventilation using self inflating bag.
Description: After oropharyngeal and nasal suctioning, if there is no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, intermittent mask and bag ventilation will be administrated at a rate 40-60 per minute using a self-inflating bag and mask with an oxygen reservoir.
Study NCT00309283 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Patients randomized to placebo will be given intramuscularly the same volume of solvent used to dissolve somatostatin every 28 days (in two intragluteal injections).
Study NCT03005886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal examination
Description: periodontal examination included the assessment of plaque index (PI), gingival index(GI), probing depth (PD), bleeding on probing (BOP) and clinical attachment level (CAL).~All subjects underwent a periodontal examination performed by the same periodontitis (ZTÇ) Prior to the study, the examiner was calibrated for reproducibility of PD and CAL measurements
Study NCT03005886 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal examination
Description: periodontal examination included the assessment of plaque index (PI), gingival index(GI), probing depth (PD), bleeding on probing (BOP) and clinical attachment level (CAL).~All subjects underwent a periodontal examination performed by the same periodontitis (ZTÇ) Prior to the study, the examiner was calibrated for reproducibility of PD and CAL measurements
Study NCT03005886 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Periodontal examination
Description: periodontal examination included the assessment of plaque index (PI), gingival index(GI), probing depth (PD), bleeding on probing (BOP) and clinical attachment level (CAL).~All subjects underwent a periodontal examination performed by the same periodontitis (ZTÇ) Prior to the study, the examiner was calibrated for reproducibility of PD and CAL measurements
Study NCT01156610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Treatment
Description: Comparison of integrated cessation counseling tools with the normal standard of care.~Both the intervention and control clinics will be provided with tools for visit-based best practices for tobacco cessation. The LMR will provide smoking status icons and tobacco treatment reminders for the primary care physicians at the time of a visit. In addition, physicians in both arms have access to decision support around medications prescribed, including bupropion and varenicline. Physicians can refer patients to tobacco cessation groups that meet periodically at each of the sites or to the Massachusetts tobacco quitline.~Outcome Assessment: Six month IVR Call: Patients in both the intervention and control practices who have not opted-out will be called six months after completing the 12-week treatment protocol. The outcome assessment script will be largely the same for intervention and control practices (except for the questions related to satisfaction with the intervention protocol).
Study NCT01156610 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Treatment
Description: Comparison of integrated cessation counseling tools with the normal standard of care.~Both the intervention and control clinics will be provided with tools for visit-based best practices for tobacco cessation. The LMR will provide smoking status icons and tobacco treatment reminders for the primary care physicians at the time of a visit. In addition, physicians in both arms have access to decision support around medications prescribed, including bupropion and varenicline. Physicians can refer patients to tobacco cessation groups that meet periodically at each of the sites or to the Massachusetts tobacco quitline.~Outcome Assessment: Six month IVR Call: Patients in both the intervention and control practices who have not opted-out will be called six months after completing the 12-week treatment protocol. The outcome assessment script will be largely the same for intervention and control practices (except for the questions related to satisfaction with the intervention protocol).
Study NCT03327753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor control exercises
Description: The first stage of the treatment involves assessment of symptoms and implementation of a retraining program designed to improve activity of muscles assessed to have poor control and reducing activity of any muscle identified to be overactive. Participants are taught how to contract these muscles independently from the superficial trunk muscles and progress until the patient are able to maintain isolated contractions of the target muscles. During this stage exercises for breathing control, posture of spine and lower limb and movement are performed. The second stage of the treatment involved the progression of the exercises towards more functional activities. Throughout this process the recruitment of the trunk muscles, posture, movement pattern and breathing are assessed and corrected.
Study NCT03327753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded activity
Description: The program is based on activities that each patient identify as problematic and that they cannot perform or have difficulty performing because of their back pain. The activities in the program are progressed in a time-contingent manner from the baseline assessed ability to a target goal set jointly by patient and therapist. Patients receive daily quotas and are instructed to only perform the agreed amount, even when they feel they are capable of doing more. Cognitive-behavioural principles are used to help patients overcome the natural anxiety associated with pain and activities. Physiotherapists use positive reinforcement, explain pain mechanisms and addressed negative behaviours and pain-related anxiety. A plan for managing relapses is developed between therapists and patients.
Study NCT02408796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-201
Study NCT03820037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ongentys
Description: single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions
Study NCT03820037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 (test)
Description: single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions
Study NCT01912729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Networked Peer Support with Peer Guide
Description: Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a peer guide. The peer guide will be another high school student around the same age as participants.
Study NCT01912729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Networked Peer Support with Clinician Coach
Description: Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a clinical psychologist.
Study NCT04597034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AN69-Oxiris
Description: To demonstrate clinical efficacy of AN69-Oxiris membrane to reach a stable MAP, with less vasopressor dosing (at least 0.1 micrograms/kg/min) after 72h of treatment, compared to a conventional membrane (standard AN69) in critically ill patients with AKI, COVID-19 infection and requirement of continuous renal replacement therapy.
Study NCT04597034 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AN69-Standard
Description: Standard treatment.
Study NCT02154126 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Glucose Monitoring Device (Senseonics)
Study NCT01986634 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laser Treatment
Description: Patient will have split face laser resurfacing as per standard of care. One side of the face will be treated with a standardized single depth laser peel. The other side of the perioral area will be treated with variant, deeper treatment to perioral rhytids.
Study NCT00057837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Arm PET: 70 mg/m2 IV over 60 minutes on days 8, 9 and 10 of each cycle. Arm PIE: 85 mg/m2 orally (divided into 2 doses, 12 hours apart) on day 3 and 10 of each cycle.
Study NCT00057837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50 mg/m2 IV over 90 minutes on days 1 and 8 of each cycle (Arm PIE only).
Study NCT00057837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan 0.75 mg/m2 IV over 30 minutes on days 1,2 and 3 of each cycle (Arm PET only).
Study NCT04419285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Locomotion task
Description: The locomotion task takes place on a Streetlab platform. The subject must follow a line on the ground, straight or composed of turns.
Study NCT04419285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Posturology task SOT (Sensory Organization Test)
Description: The task takes place on a Streetlab platform with uniform walls without decorations in order to remove any localization element.
Study NCT04419285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The quality of life questionnaire
Description: Study the correlations between the subjects' quality of life scores and the results during behavioral tests. Identify the subjective parameters most sensitive to sensory-motor performance.
Study NCT01107756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LENOGRASTIM (GRANOGYTE 34)
Description: Pharmaceutical form: solution Route of administration: intravenous Dose regimen:recommended dosing as per Granocyte 34 package insert
Study NCT00712322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Following a 7-day washout period, participants received darifenacin liquid oral suspension up to 14 days.
Study NCT03608553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Guided Focused Ultrasound
Description: Blood Brain Barrier Disruption using FUS
Study NCT02375633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW-330SR2
Study NCT02375633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pelubiprofen
Study NCT01755494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg
Description: Saxagliptin oral tablet 5mg, single dose
Study NCT01755494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR 500 mg
Description: Metformin XR oral tablet 500 mg, single dose
Study NCT01755494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mertformin XR 2 x 500 mg
Description: Metformin XR oral tablet 2 x 500 mg, single dose
Study NCT01755494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Komboglyze XR 5/500 mg
Description: oral FDC tablet (saxagliptin 5 mg and metformin 500 mg), single dose
Study NCT01755494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Komboglyze XR 5/1000 mg
Description: oral FDC tablet (saxagliptin 5 mg and metformin 1000 mg), single dose
Study NCT04651725 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Patients were planned to complete exercise sessions 3 times a week for 12 weeks, each lasting 35 minutes per day.
Study NCT03005886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GCF sampling
Description: GCF samples were collected using commercially available periopaper . The sample site was gently air-dried and all supragingival plaque was removed. The area was carefully isolated with cotton rolls and a saliva ejector was used to prevent the samples from being contaminated by saliva. The paper strips were inserted into the pockets until slight resistance was felt and left in place for 30s.
Study NCT03005886 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GCF sampling
Description: GCF samples were collected using commercially available periopaper . The sample site was gently air-dried and all supragingival plaque was removed. The area was carefully isolated with cotton rolls and a saliva ejector was used to prevent the samples from being contaminated by saliva. The paper strips were inserted into the pockets until slight resistance was felt and left in place for 30s.
Study NCT05033509 — intervention group
Intervention type: OTHER
Intervention: supervision the Kidney fonction on ECMO
Description: patients who benefited from ECMO, and presented an acute kidney injury afterwards
Study NCT02260245 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Team training using the TeamSTEPPS model
Description: Two or three master trainers from each affiliate will be undergo train-the-trainer training to bring back to their affiliate.
Study NCT02511951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreaticojejunostomy
Description: To create the posterior suturing layers, the needle is inserted from the posterior interior side of the pancreatic duct, passing through the dorsal region of the parenchyma of the pancreatic stump to the posterior surface of the pancreas approximately 0.5 cm distal to the cut edge. The other side of the needle starts from the inside of the jejunum lumen to the subserosa and then passes through the seromuscular layer to the posterior surface of the bowel.The anterior suturing layer is performed in the same manner.~Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used.
Study NCT02511951 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreaticojejunostomy
Description: To create the posterior suturing layers, the needle is inserted from the posterior interior side of the pancreatic duct, passing through the dorsal region of the parenchyma of the pancreatic stump to the posterior surface of the pancreas approximately 0.5 cm distal to the cut edge. The other side of the needle starts from the inside of the jejunum lumen to the subserosa and then passes through the seromuscular layer to the posterior surface of the bowel.The anterior suturing layer is performed in the same manner.~Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used.
Study NCT02450526 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A